Picard Medical is trading 6.81% down at $8.90 after the August 25, 2026 announcement that Bragar Eagel & Squire is investigating potential fiduciary-duty claims.
- Inquiry alleges social-media promotion, nominee accounts, coordinated share activity, and omitted risk disclosures.
- Announcement followed two consecutive sessions of extreme gains, raising legal/shareholder-risk sensitivity.
- Available release listing does not report August 26 volume or quantify its impact on the decline; confidence is medium because the investigation is company-specific, with limited independent coverage.